Article metrics
PDF
Other content recommended for you
- Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials
- Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society
- Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries
- Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
- Children’s views on taking medicines and participating in clinical trials
- Nusinersen for SMA: expanded access programme
- Engaging African ancestry participants in SLE clinical trials
- Accessing unproven interventions in the COVID-19 pandemic: discussion on the ethics of ‘compassionate therapies’ in times of catastrophic pandemics
- Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
- Expanded access: growing importance to public health